TARSILA Real-World Evidence Studie (TARSILA)
Real-world Effectiveness of maTernAl RSVpreF vaccInation Against RSV-associated Acute Respiratory ilLness in Infants in BrAzil (TARSILA Study): a Multicentre, Prospective, Test-negative, Case-Control Study
The overall objective of Tarsila Study is to estimate the real-world vaccine effectiveness of maternal RSVpreF immunization during pregnancy in Brazil against medically attended (inpatient and outpatient) respiratory syncytial virus-associated acute respiratory illness in infants. To achieve this, two multicenter, prospective, test-negative case-control studies will be conducted among infants with ARI: the TARSILA Inpatient Study, evaluating hospitalized infants and the TARSILA Outpatient Study, evaluating infants managed in outpatient settings.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Tarsila comprises two multicenter, prospective, case-control studies using a test-negative design in Southern Brazil (states of Rio Grande do Sul, Santa Catarina, and Paraná). The Tarsila Inpatient study will enroll infants hospitalized due to acute respiratory illness and will be conducted at referral hospitals. The Tarsila Outpatient study will enroll infants with acute respiratory illness managed in outpatient settings and will be conducted at outpatient healthcare facilities. Both studies are aligned with the nationwide introduction of maternal RSVpreF vaccination in December 2025, with enrollment occurring from April, 2026 to September, 2028. In both studies, the same clinical case definition will be applied to cases and controls. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) for RSV will be prospectively performed to classify case infants (RT-qPCR positive for RSV) and control infants (RT-qPCR negative for RSV). Maternal RSVpreF vaccination status and potential confounders will be assessed through structured interviews and review of medical records.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Maicon Falavigna, MD PhD
- Telefoonnummer: +55 51 2399 1750
- E-mail: research@inovamedical.com.br
Studie Locaties
-
-
Paraná
-
Cascavel, Paraná, Brazilië, 85818-130
- Werving
- Unidade de Pronto Atendimento Veneza
-
Contact:
- Maicon Falavigna
- Telefoonnummer: +555123991750
- E-mail: research@inovamedical.com.br
-
Curitiba, Paraná, Brazilië, 80060-900
- Werving
- Complexo do Hospital de Clínicas da Universidade Federal do Paraná
-
Contact:
- Maicon Falavigna
- Telefoonnummer: +555123991750
- E-mail: research@inovamedical.com.br
-
Hoofdonderzoeker:
- Cristina de Oliveira Rodrigues
-
Curitiba, Paraná, Brazilië, 80240-031
- Werving
- Hospital Infantil Pequeno Príncipe
-
Contact:
- Maicon Falavigna
- Telefoonnummer: +555123991750
- E-mail: research@inovamedical.com.br
-
Hoofdonderzoeker:
- Heloisa Ihle Garcia Giamberardino
-
Marechal Cândido Rondon, Paraná, Brazilië, 85960-000
- Werving
- Unidade de Pronto Atendimento 24 Horas Dr. Edgar Netzel
-
Contact:
- Maicon Falavigna
- Telefoonnummer: +555123991750
- E-mail: research@inovamedical.com.br
-
Palotina, Paraná, Brazilië, 85950-000
- Werving
- Unidade de Saúde Central de Palotina
-
Contact:
- Maicon Falavigna
- Telefoonnummer: +555123991750
- E-mail: research@inovamedical.com.br
-
Toledo, Paraná, Brazilië, 85902-480
- Werving
- Unidade de Pronto Atendimento II de Toledo
-
Contact:
- Maicon Falavigna
- Telefoonnummer: +555123991750
- E-mail: research@inovamedical.com.br
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazilië, 91350-200
- Werving
- Hospital Nossa Senhora da Conceição
-
Contact:
- Maicon Falavigna, PhD
- Telefoonnummer: +555123991750
- E-mail: research@inovamedical.com.br
-
Hoofdonderzoeker:
- Fernanda H Varela
-
Porto Alegre, Rio Grande do Sul, Brazilië, 90035-903
- Werving
- Hospital de Clínicas de Porto Alegre
-
Contact:
- Maicon Falavigna
- Telefoonnummer: +555123991750
- E-mail: research@inovamedical.com.br
-
Hoofdonderzoeker:
- Ricardo Becker Feijó
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Bemonsteringsmethode
Studie Bevolking
Infants with acute respiratory illness (ARI)
Beschrijving
Tarsila Inpatient Study
Inclusion Criteria
- Infant born in Brazil.
- Mother resident in Brazil during the related pregnancy.
- Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
- Infant ≤360 days of age at time of RSV specimen collection.
- Infant born at ≥37 weeks of gestational age.
- Infant hospital admission for at least 24 hours with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).
Exclusion Criteria:
- Maternal or infant receipt of any other licensed or investigational RSV preventive product.
- Infant receipt of blood transfusion or other blood products containing antibodies since birth.
- Infant previously enrolled in this study.
- Lack of informed consent from the mother or the infant's legal guardian.
- Absent or inconclusive RT-qPCR result for RSV.
- Birth to a mother whose RSVpreF vaccination status could not be confirmed.
Tarsila Outpatient Study
Inclusion Criteria:
- Infant born in Brazil.
- Mother resident in Brazil during the related pregnancy.
- Infant date of birth 14 days or more after start of the first national RSVpreF vaccination campaign to ensure potential to have been born to an RSVpreF-vaccinated mother.
- Infant ≤360 days of age at time of RSV specimen collection.
- Infant born at ≥37 weeks of gestational age.
- Infant presentation to an outpatient healthcare facility with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring).
Exclusion Criteria:
- Mother or infant receipt of any other licensed or investigational RSV preventive product.
- Infant receipt of blood transfusion or other blood products containing antibodies since birth.
- Lack of informed consent from the mother or the infant's legal guardian.
- Absent or inconclusive RT-qPCR result for RSV.
- Birth to a mother whose RSVpreF vaccination status could not be confirmed.
- Enrollment in the study within the previous 30 days. If the interval exceeds 30 days, infants will be excluded if any previous episode tested positive for RSV.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Observatiemodellen: CASE_CONTROL
- Tijdsperspectieven: PROSPECTIVE
Aantal groepen / cohorten
Cohorten en interventies
Groep / CohortGroep / Cohort |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Cases
Infants with a positive respiratory syncytial virus result on a nasal swab specimen |
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery. |
|
Controls
Infants with a negative respiratory syncytial virus result on a nasal swab specimen |
For both studies, the primary exposure is maternal receipt of respiratory syncytial virus bivalent prefusion F vaccination during pregnancy in accordance with the Brazilian National Immunization Program recommendation (24⁺⁰/₇ to 36⁺⁶/₇ weeks' gestation) with the receipt of the vaccine 14 days or more before delivery. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) Hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
Hospitalization due to RT-qPCR-confirmed RSV-positive lower respiratory tract disease, defined as cough or difficulty breathing, symptom onset within the preceding 10 days, and at least one of the following: tachypnea (respiratory rate ≥60 breaths/min for infants <2 months; ≥50 breaths/min for infants 2-12 months), oxygen saturation (SpO₂) <95%, or chest wall indrawing). |
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up to 180 days (Tarsila Outpatient Study)
Tijdsspanne: Occurring ≤180 days after birth.
|
RT-qPCR-confirmed RSV-positive with signs and symptoms meeting the case definition of ARI, defined as the presence of any of the following: nasal secretion for ≥24 hours; respiratory distress, labored breathing, or tachypnea (respiratory rate ≥60 breaths/min for infants <2 months or ≥50 breaths/min for infants 2-12 months); cough; inability to feed for any period due to respiratory symptoms; apnea; or other relevant respiratory symptoms (examples include but are not limited to wheezing, crackles, and nasal flaring). |
Occurring ≤180 days after birth.
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, defined as LRTD plus at least one of the following: respiratory rate ≥70 breaths/min (if <2 months) or ≥60 breaths/min (if ≥2 months); SpO₂ <93%; requirement for high-flow oxygen, non-invasive, or invasive mechanical ventilation; intensive care unit (ICU) admission for >4 hours; or unresponsiveness/loss of consciousness) . |
Hospitalization occurring ≤180 days after birth
|
|
Severe Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by subgroups (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up to 180 days by Subgroups (Tarsila Outpatient Study)
Tijdsspanne: ARI occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by: gestational age at RSVpreF vaccination, time from RSVpreF vaccination to birth, and time intervals of infant age at illness. |
ARI occurring ≤180 days after birth
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Lower respiratory Tract Disease (LRTD) ICU hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
|
RT-qPCR-confirmed RSV-positive LRTD ICU hospitalization. ICU admission occuring at any point during the index hospitalization. |
Hospitalization occurring ≤180 days after birth. ICU admission occuring at any point during the index hospitalization
|
|
Lower respiratory Tract Disease (LRTD) prolonged hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD long hospital stay (≥11 days) . |
Hospitalization occurring ≤180 days after birth
|
|
Lower respiratory Tract Disease (LRTD) in-hospital death among infants aged up to 180 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
|
RT-qPCR-confirmed RSV-positive LRTD in-hospital death. |
Hospitalization occurring ≤180 days after birth. Death occuring at any point during the index hospitalization.
|
|
Hospitalization for lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive LRTD hospitalization, analyzed by time intervals of infant age at illness. |
Hospitalization occurring ≤360 days after birth
|
|
Severe lower respiratory Tract Disease (LRTD) hospitalization among infants aged up to 180 days by exploratory subgroups (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by:
|
Hospitalization occurring ≤180 days after birth
|
|
Hospitalization for severe lower respiratory tract disease (LRTD) among infants aged up to 360 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive severe LRTD hospitalization analyzed by time intervals of infant age at illness. |
Hospitalization occurring ≤360 days after birth
|
|
Acute respiratory illness (ARI) hospitalization among infants aged up to 180 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI hospitalization |
Hospitalization occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) hospitalization among infants aged up to 360 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive ARI hospitalization. |
Hospitalization occurring ≤360 days after birth
|
|
Lower respiratory Tract Disease (LRTD) Hospitalization due to Human Metapneumovirus (HMPV) among infants aged up to 180 days (Tarsila Inpatient Study)
Tijdsspanne: Hospitalization occurring ≤180 days after birth
|
RT-qPCR-confirmed HMPV-positive LRTD hospitalization |
Hospitalization occurring ≤180 days after birth
|
|
Acute Respiratory Illness (ARI) among infants aged up to 180 days by exploratory subgroups (Tarsila Outpatient Study)
Tijdsspanne: ARI occurring ≤180 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by:
|
ARI occurring ≤180 days after birth
|
|
Acute respiratory illness (ARI) among infants aged up 360 days (Tarsila Outpatient Study)
Tijdsspanne: ARI occurring ≤360 days after birth
|
RT-qPCR-confirmed RSV-positive ARI analyzed by time intervals of infant age at illness. |
ARI occurring ≤360 days after birth
|
|
Lower respiratory Tract Disease (LRTD) among infants aged up to 180 days (Tarsila Outpatient Study)
Tijdsspanne: LRTD occurring ≤180 days after birth.
|
RT-qPCR-confirmed RSV-positive LRTD. |
LRTD occurring ≤180 days after birth.
|
|
Lower respiratory Tract Disease (LRTD) infants aged up to 360 days (Tarsila Outpatient Study)
Tijdsspanne: LRTD occurring ≤360 days after birth.
|
RT-qPCR-confirmed RSV-positive LRTD. |
LRTD occurring ≤360 days after birth.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Medewerkers
Medewerkers
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Maicon Falavigna, Inova Medical
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Andere studie-ID-nummers
Andere studie-ID-nummers
- CAAE 95166426.7.1001.0008
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .